PRPH

Across TCGA pan-cancer cohorts, PRPH Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRPH data layer compared with 19 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PRPH Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRPH expression acts as an unfavorable survival marker.

BLCA, LUAD, and CESC are the cancer types where PRPH Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.063	0.688	<.001	30	view →
LUAD	OS	Median	All	0.017	0.812	<.001	24	view →
CESC	OS	Median	II,III,IV	0.128	0.765	<.001	16	view →
SCLC	DFS	Median	All	0.178	0.631	.005	6	view →
LUSC	OS	Median	II,III,IV	0.279	0.742	.032	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRPH–BLCA (OS)

Open the BLCA breakdown →